SGEN - シアトル・ジェネティクス （Seattle Genetics Inc.） シアトル・ジェネティクスSGENのチャート
SGENの企業情報
| symbol | SGEN |
|---|---|
| 会社名 | Seattle Genetics Inc （シアトル・ジェネティクス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: Biological Products (No Diagnostic Substances) |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 シアトル・ジェネティクス（Seattle Genetics Inc.）は主に癌に対するモノクローナル抗体に基づく治療薬の開発・商品化に従事するバイオテクノロジー会社。同社の候補薬剤であるADCETRIS（brentuximab vedotin）は米国食品医薬品局（FDA）より二つの適応症における承認を受けた。一つは、自家幹細胞移植（ASCT）の障害が発生した後、またはASCT候補者ではない患者に対する二つ以上の前マルチエージェントの化学療法レジメンの障害が発生した後に、ホジキンリンパ腫患者に対する治療である。もう一つは、前マルチエージェントの化学療法レジメンの障害が発生した後に、全身未分化大細胞リンパ腫（ALCL）の患者に対する治療である。ADCETRISは抗体医薬品複合体（ADC）であり、抗CD30モノクローナル抗体により構成され、同社の技術を利用して、微小管破壊剤であるモノメチルアウリスタチンE（MMAE）にプロテアーゼ切断可能なリンカーで接続している。 シアトル・ジェネティクスは、米国のバイオテクノロジ―企業。抗体を使用した癌の治療薬の開発と商品化に従事。同社は抗体が持つ標的化能力を利用し、殺細胞剤を直接がん細胞に届けるようにデザインされた技術抗体薬物複合体（ADC）の開発に特化している。武田薬品工業株式会社と提携し、ADCETRISの共同開発を行う。 seattle genetics, co-founded by clay siegall, is a biotechnology company leading the field of antibody-drug conjugates (adcs) for the treatment of cancer. our technology is designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. our lead program, adcetris® (brentuximab vedotin), is the first in a new class of adcs and, in collaboration with takeda pharmaceutical company limited, is approved in more than 55 countries. to expand on the adcetris opportunity, we are conducting a broad clinical development program to evaluate its therapeutic potential in a range of other lymphoma and non-lymphoma settings. seattle genetics is also advancing a robust pipeline of clinical-stage programs, including sgn-cd19a, sgn-cd33a, sgn-liv1a, sgn-cd70a, asg-22me, asg-15me and sea-cd40. seattle genetics has collaborations for its adc technology with a number of leading biotechnology and pharmaceutical companies, including abbvie, agensys |
| 本社所在地 | 21823 30th Drive SE Bothell WA 98021 USA |
| 代表者氏名 | Clay B. Siegall Clay B. Siegall |
| 代表者役職名 | Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者（CEO） |
| 電話番号 | +1 425-527-4000 |
| 設立年月日 | 35612 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2001年 |
| 従業員数 | 1100人 |
| url | www.seattlegenetics.com |
| nasdaq_url | https://www.nasdaq.com/symbol/sgen |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -173.43500 |
| 終値（lastsale） | 77.17 |
| 時価総額（marketcap） | 12253938665.94 |
| 時価総額 | 時価総額（百万ドル） 11401.23 |
| 売上高 | 売上高（百万ドル） 575.65900 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 10953.253 |
| 当期純利益 | 当期純利益（百万ドル） -44.62200 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Seattle Genetics Inc. revenues increased 43% to $310.8M. Net loss decreased 70% to $35.4M. Revenues reflect Net product sales increase of 51% to $217.8M Collaboration and license agreement reve increase of 31% to $56.7M Royalty revenues increase of 23% to $36.2M. Lower net loss reflects Investment and other income (loss) net increase from $2.2M to $88.7M (income). |
SGENのテクニカル分析
SGENのニュース
Seagen gains as antitrust deadline for Pfizer purchase nears on Monday 2023/06/09 18:52:57 Seeking Alpha
Seagen (SGEN) rose 1.2% ahead of a Monday deadline for an antitrust initial review of its planned $43 billion sale to Pfizer (PFE)
If You Invested $1000 In This Stock 10 Years Ago, You Would Have $5,800 Today 2023/06/07 15:30:25 Benzinga
Seagen (NASDAQ: SGEN ) has outperformed the market over the past 10 years by 9.17% on an annualized basis producing an average annual return of 19.29%. Currently, Seagen has a market capitalization of $36.75 billion. Buying $1000 In SGEN: If an … Full story available on Benzinga.com
Profit From The Pfizer Takeover Of Seagen 2023/06/07 06:08:45 Seeking Alpha
Pfizer is set to acquire Seagen for $43 billion, with the deal expected to close later this year or in early 2024, subject to regulatory approvals. Click here for a detailed analysis.
3 Undervalued Biotech Stocks to Buy Before They Blast Off 2023/06/02 11:55:32 InvestorPlace
When investors hear the words “undervalued biotech stocks to buy,” they frequently think of companies in the clinical trial stage. That’s understandable. If you can buy a company’s stock before it releases a game-changing drug or therapeutic into the market, you can make a fortune. That line of thinking was displayed in 2020 when many biotech companies raced to produce a Covid-19 vaccine. But every investor also knows that many of those moonshots never pan out. That’s not the kind of uncertainty you need in this current market. A better option is to look at the companies that already have FDA-approved drugs in the market and a pipeline of potential products on the way. This increases your chance of success. And the good news is that there are several high-potential biotech stocks . By this, I mean the stocks are trading below the average price-to-earnings of the biotech sector, which is around 19x as of this writing. These stocks also have other catalysts that make them compelling stocks to buy.
Seagen To Be Acquired By Pfizer For $43 Bln 2023/05/30 21:18:00 Finanz Nachrichten
WASHINGTON (dpa-AFX) - The biotechnology company Seagen Inc. (SGEN) announced on Tuesday that its stockholders have approved a proposal under which Pfizer will acquire Seagen.Under the merger agre…
Seattle Genetics''s Return On Capital Employed Overview 2022/08/04 14:07:57 Benzinga
According to Benzinga Pro data, during Q2, Seattle Genetics (NASDAQ: SGEN ) posted sales of $497.50 million. Earnings were up 1.22%, but Seattle Genetics still reported an overall loss of $134.83 million. Seattle Genetics collected $426.46 million in revenue during Q1, but reported earnings showed a $136.49 million loss. What Is ROCE? Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a … Full story available on Benzinga.com
Seagen With And Without A Merck Buyout 2022/08/04 06:20:53 Seeking Alpha
Investors have focused on rumors of a Merck acquisition of Seagen. Read why I would wait on SGEN stock and re-evaluate if the deal doesn''t happen.
Merck Has Good Reason to Buy a Cancer-Drug Biotech 2022/08/02 11:32:42 The Washington Post
Seagen’s innovative technology for delivering chemotherapy is blossoming.
JPMorgan Assumes Seagen at Overweight 2022/08/01 21:15:03 Investing.com
https://www.investing.com/news/pro/seagen-receives-investment-bank-analyst-rating-update-432SI-2859855
Tekla Capital Management LLC Buys 2, Sells 3 in 2nd Quarter 2022/07/29 23:00:05 GuruFocus
Related Stocks: SGEN , VRTX , MCK , MDT , ISRG ,
Seagen With And Without A Merck Buyout 2022/08/04 06:20:53 Seeking Alpha
Investors have focused on rumors of a Merck acquisition of Seagen. Read why I would wait on SGEN stock and re-evaluate if the deal doesn''t happen.
Merck Has Good Reason to Buy a Cancer-Drug Biotech 2022/08/02 11:32:42 The Washington Post
Seagen’s innovative technology for delivering chemotherapy is blossoming.
JPMorgan Assumes Seagen at Overweight 2022/08/01 21:15:03 Investing.com
https://www.investing.com/news/pro/seagen-receives-investment-bank-analyst-rating-update-432SI-2859855
Tekla Capital Management LLC Buys 2, Sells 3 in 2nd Quarter 2022/07/29 23:00:05 GuruFocus
Related Stocks: SGEN , VRTX , MCK , MDT , ISRG ,
Seagen Q2 Earnings - Better Than Expected, Mum On M&A, Lifts Outlook 2022/07/29 14:42:18 Benzinga
Seagen Inc (NASDAQ: SGEN ) released its Q2 earnings and kept quiet on any update on the M&A front as rumors fly around a potential Merck & Co Inc (NYSE: MRK ) buyout. Related: Merck''s Potential Buyout Of Seagen Expected Within Next Few Weeks: Report . Seagen reported Q2 sales of $497.5 million, up 28% Y/Y, … Full story available on Benzinga.com